Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-BB4 in healthy volunteers
NCT05232175Phase 1Completed
- Sponsor
- Alteogen
- Start
- Jan 2022
- Primary completion
- Aug 2022
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of tergase (5 arms), sponsored by Alteogen. Primary endpoints: Incidence Rate of Drug Allergy Following ID Injection of the IP at 2 days and Injection-site Treatment Emergent Adverse Events at 4 weeks. Started Jan 2022; status: completed.
02
Drugs
tergase
Beyond the preview
Go deeper on NCT05232175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232175.